Roivant and Priovant reported positive Phase 3 results for Lisraya (an immune-modifying therapy) in non-infectious uveitis, describing efficacy over placebo across two trials covering 371 patients. Lisraya had already received approval for dermatomyositis, and Roivant said it plans to seek an expanded FDA approval path. The update is intended to extend the drug’s addressable market from a rare skin disease into a broader inflammatory eye population, with Roivant estimating a sizable U.S. patient pool and adoption potential relative to existing biologic regimens. For development teams, the key follow-through will be how Roivant sequences labeling into ocular endpoints and manages safety monitoring expectations for longer-term use in a chronic condition.